SureSeq™ CLL + CNV Panel
The SureSeq CLL + CNV Panel has been designed in collaboration with recognised cancer experts to detect 12 key genes and 5 chromosomal regions implicated in CLL progression.
Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in adults. A wide variety of chromosomal abnormalities are associated with CLL, ranging from single nucleotide variants (SNVs) and insertions/deletions (indels) up to large copy-number variations (CNVs), including trisomies.
The SureSeq CLL + CNV Panel has been designed in collaboration with recognised cancer experts to detect 12 key genes and 5 chromosomal regions implicated in CLL progression (Table 1). The SureSeq CLL + CNV Panel alleviates the burden of running multiple assays and streamlines your CLL research to deliver a comprehensive genomic profile for each CLL sample using a single workflow.
The SureSeq CLL + CNV Panel offers:
- Unparalleled uniformity and high depth of coverage - detect low-frequency SNVs and indels
- CNV detection ranging from loss of single exons to full chromosome arms and
trisomy 12 - profile your samples for CNVs in the 5 most commonly aberrant regions in CLL
- Time savings - replace multiple assays with a single NGS panel, increasing throughput and
reducing turnaround time
- Complimentary data analysis software - analyse your data with Interpret, OGT’s powerful and
easy-to-use analysis solution for accurate identification of all variants and CNVs
Contains the latest evidence-based content
Investigating both chromosomal aberrations and SNVs/indels is imperative to advance research into CLL progression and treatment. Structural abnormalities are common in CLL and found in more than 80% of CLL cases, the most frequent being del(13q), del(11q), del(17p), del(6q) and trisomy 121. Some of these CNVs cover important tumour suppressors, such as del(17p) resulting in the loss of the TP53 gene. More recently, other genes have also been found to be mutated in CLL, including NOTCH1, SF3B1, MYD88 and BIRC3, adding to the genomic complexity of this leukaemia2.
Due to this genetic heterogeneity, current analysis strategies for CLL require multiple methods to obtain a comprehensive genetic picture, often using microarray or fluorescence in situ hybridisation (FISH) to detect structural abnormalities in combination with NGS for somatic variants. With OGT’s SureSeq CLL + CNV Panel, you can now obtain a more complete understanding of the genetic makeup of CLL progression in each sample using a single assay.
Table 1: The SureSeq CLL + CNV Panel targets the 5 most common chromosomal regions implicated in CLL and 14 genes, including 2 genes and 24 SNPs for easy sample tracking.
Superior coverage uniformity allowing reliable variant and somatic CNV detection
OGT’s expert bait design delivers outstanding uniformity and depth of coverage, offering confident detection of low frequency SNVs and indels down to 1% minor allele frequency (MAF) in 14 genes (Figure 1), including 2 genes and 24 SNPs to allow for easy sample tracking3.
Figure 1: Illustration of the excellent uniformity and high depth of coverage allowing confident detection of (A) a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and (B) a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.
The SureSeq CLL + CNV Panel covers the 5 most common CNVs in CLL and enables detection down to 10% MAF, corresponding to 20% tumour content. Compared to array data, often considered the gold standard for CNV detection, the events reported with the SureSeq CLL + CNV Panel were 100% concordant, even in genomic regions containing multiple aberrations (Figures 2 - 3). More so, facilitated by OGT’s excellent bait design, loss-of-heterozygosity (LOH) can be identified. With a CNV size detection range from single exon to whole gene, up to complete loss of a chromosomal arm and whole chromosome gains (trisomy 12), your data provides a more comprehensive genetic picture for each sample from a single assay.
Figure 2: 42.7Mb deletion of 11q covering ATM.
Figure 3: 0.6Mb biallelic loss called within a larger ~1Mb single allele deletion in the region covering DLEU2/DLEU1/DLEU7 on chromosome 13q.
Complimentary Interpret software
Interpret is OGT’s powerful and easy-to-use data analysis solution, facilitating analysis and visualisation of a wide range of somatic variants and structural aberrations. Designed to work seamlessly with all SureSeq panels, Interpret perfectly complements the SureSeq CLL + CNV Panel, delivering fast and accurate detection of all SNVs, indels, LOH and CNVs covered by the panel. Following detection, all events can be readily visualised in the user-friendly variant browser, for an effortless translation of all your CLL data into meaningful results (Figure 4).
Figure 4: Following analysis, all variants and CNVs are visualised for easy interpretation in OGT’s Interpret. In this example a trisomy 12 is detected, showing a reliable gain call across the whole chromosome.
Bespoke panel content
Does the SureSeq CLL + CNV Panel not meet your exact requirements? With OGT, you never have to sequence genes you’re not interested in and can always modify each panel to what’s most relevant for your research. Choose from our regularly updated, expert-curated library of pre-optimised cancer content to create your ideal custom SureSeq myPanel™ CLL Panel, or order the SureSeq CLL + CNV Panel right off the shelf.
The SureSeq CLL + CNV Panel in numbers
|SureSeq CLL + CNV Panel (16 reactions)||Enrichment baits sufficient for 16 samples; SureSeq Interpret Software||602022-16||Get a quote|
|SureSeq CLL + CNV Panel (96 reactions)||Enrichment baits sufficient for 96 samples; SureSeq Interpret Software||602022-96
||Get a quote|
|SureSeq NGS Library Preparation Complete Solution (16)
||Bundle of 1x SureSeq library preparation kit (16), containing adaptors, PCR primers and enzymes, 1x SureSeq NGS Index Kit – Collection A, 1x SureSeq Hyb & Wash Kit (16), 1x Dynabeads M270 Streptavidin (2ml) and 1x AMPure XP beads (10ml). Sufficient for 16 samples
||Find out more|
|SureSeq NGS Library Preparation Complete Solution (48)
||Bundle of 3x SureSeq NGS Library Preparation Kit (16), containing adaptors, PCR primers and enzymes, 1x SureSeq NGS Index Kit – Collection B, 3x SureSeq NGS Hyb & Wash Kit (16), 3x Dynabeads M270 Streptavidin (2ml)* and 3x AMPure XP beads (10ml)*. Sufficient for 48 samples
||Find out more|
* Only for use with OGT's NGS panels
- Döhner et al., N Engl J Med 2000;343:1910-1916
- Rossi et al., Blood 2013;121:1403-1412
- Pengelly et al., Genome Med 2013;5:89
SureSeq: For Research Use Only; Not for Diagnostic Procedures. This webpage and its contents are © Oxford Gene Technology IP Limited – 2020. All rights reserved. OGT™ and SureSeq™ are trademarks of Oxford Gene Technology IP Limited. The SureSeq NGS Library Preparation Kit was jointly developed between Oxford Gene Technology and Bioline Reagents Limited. Dynabeads is a trademark of Thermo Fisher Scientific and AMPure® is a registered trademark of Beckman Coulter Inc.
Optimised, 1-day hybridisation-based NGS protocol yields 1% variant detection in MPN samples, as quickly and cost-effectively as multiplex PCR
Presented at AMP 2016, this poster outlines how the SureSeq™ Core MPN Panel can accurately detect alleles down to 1% variant allele fraction (VAF) in JAK2 (V617F) at a read depth of >1000x, facilitating reliable detection.
The accurate detection by next-generation sequencing (NGS) of difficult to sequence genes (CALR, CEBPA, FLT3) associated with myeloid disorders using a hybridisation-based enrichment approach
Presented at CGC 2017, this poster highlights the excellent uniformity of coverage obtained from the hybridisation-based enrichment using the SureSeq myPanel NGS Custom AML Panel.
The analysis of myeloproliferative neoplasm samples using a rapid (30 minute) hybridisation-based enrichment protocol for next-generation sequencing (NGS)
Presented at the CGC 2017 annual summer meeting in Denver, USA, this poster illustrates the excellent quality data generated by the OGT 1-day hybridisation-based SureSeq LPK protocol in combination with the SureSeq Core MPN Panel.
The application of a hybridisation-based next-generation sequencing (NGS) enrichment panel for the analysis of key genes involved in ovarian and breast tumours using DNA from FFPE samples
This poster illustrates the SureSeq™ hybridisation-based approach as a robust method for the identification of germline and somatic mutations in TP53, BRCA1, and BRCA2.
The application of a hybridisation-based NGS enrichment panel for the analysis of somatic variants in tumour samples and reference standards
Presented at AGT 2017, this poster outlines the application of a hybridisation-based NGS enrichment panel for the analysis of solid tumour somatic variants, demonstrating 100% concordance in variant detection in both genomic and formalin-compromised DNA.
The application of a one-day hybridisation-based enrichment protocol for NGS incorporating a rapid (30 minute) hybridisation step
Presented at AGT 2017, this poster outlines how OGT has optimised a one-day hybridisation-based enrichment protocol for NGS incorporating a rapid 30 hybridisation step.
The use of a hybridisation-based NGS enrichment panel for the confident identification of a broad range of low frequency variants from as little as 50ng of challenging clinical research FFPE samples
Presented at AMP 2016, this poster outlines how the SureSeq FFPE DNA Repair Mix significantly improves NGS library yields, with an increase of mean target coverage (increased by >2.2 fold), resulting in more meaningful data.
An integrated approach to profiling haematological disorders
For accurate detection of all types of genetic aberrations, various technologies are used. View OGT's integrated portfolio of products that allow the accurate analysis of haematological disorders.
An integrated approach to tumour profiling
Various technologies are available to study the mutations that cause cancer, but none is capable of accurate detection of all types of genetic aberrations. View OGT's integrated portfolio of products that allow the accurate analysis of solid tumours.
The role of NGS in stratified cancer medicine
In this white paper, two Clinical Scientists, Dr Matthew Smith and Dr George Burghel, share their views on the use of NGS in cancer genomics and its integration into the laboratory.
Understanding myeloid disorders with next-generation sequencing
This white paper describes how OGT’s SureSeq™ Myeloid Panel helps researchers identify and decipher the complex genetic origins of myeloproliferative disorders.
SureSeq myPanel™ NGS Custom Cancer Panels
SureSeq™ CLL + CNV Panel
SureSeq™ NGS Library Preparation Kit
SureSeq myPanel™ NGS Custom Cancer Panels Full Gene List
We now have 120 genes available for our SureSeq myPanel NGS Custom Cancer Panels. View and download a complete list of available cancer gene content.
OGT Product Catalog - USA and Canada
Including Cytocell® FISH probes for Constitutional Cytogenetics and Hematology/Pathology Cytogenetics, CytoSure™ NGS and Array Products for Cytogenetics and Rare Disease Research and SureSeq™ NGS Products for Hematology and Solid Tumor Cancer Research.
OGT Product Catalogue
Including Cytocell® FISH Probes for Cancer and Inherited Genetic Disease, CytoSure™ NGS and Array Products for Cytogenetics and Rare Disease, and SureSeq™ NGS Products for Haematology and Solid Tumour Cancers.
Evaluation of enzymatic DNA digestion as an alternative to mechanical DNA fragmentation (sonication) for targeted NGS using the SureSeq™ Myeloid Panel
DNA fragmentation is a crucial first step in the preparation of libraries for NGS. In this application note, Oxford Gene Technology has evaluated an alternative method of fragmentation using the NEBNext® dsDNA Fragmentase®.
Improving experimental reproducibility through automated hybridisation-based NGS library preparation
In this app note, an Agilent Bravo A Automated Liquid Handling Platform was configured to run the SureSeq NGS library preparation protocol. The results demonstrate marked improvement not only in hands-on-time, but also a number of quality metrics.
Selecting the best NGS enrichment assay for your needs
With NGS now in routine use for a broad range of research and clinical applications, this application note details the value of making the correct choice for the initial sequence enrichment step.